tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SE:HNSA Stock Latest News

Imlifidase’s Accelerated Approval Momentum and Long‑Term Graft Outcomes Support a Buy Rating on Hansa Biopharma
RatingsImlifidase’s Accelerated Approval Momentum and Long‑Term Graft Outcomes Support a Buy Rating on Hansa Biopharma
4d ago
Hansa Biopharma Wins FDA Review Acceptance for Imlifidase Kidney Transplant Therapy
PremiumCompany Announcements
Hansa Biopharma Wins FDA Review Acceptance for Imlifidase Kidney Transplant Therapy
5d ago
Hansa Biopharma price target lowered to SEK 103 from SEK 111 at H.C. Wainwright
PremiumThe Fly
Hansa Biopharma price target lowered to SEK 103 from SEK 111 at H.C. Wainwright
11d ago
Hansa Biopharma Earnings Call Marks Pivotal 2026 Pivot
PremiumCompany Announcements
Hansa Biopharma Earnings Call Marks Pivotal 2026 Pivot
11d ago
Hansa Biopharma Delivers Strong Q4 Growth and Files FDA Application for Imlifidase
PremiumCompany Announcements
Hansa Biopharma Delivers Strong Q4 Growth and Files FDA Application for Imlifidase
12d ago
Hansa Biopharma Sets February Date for 2025 Year-End Results Call
PremiumCompany AnnouncementsHansa Biopharma Sets February Date for 2025 Year-End Results Call
28d ago
Hansa Biopharma Wins 2025 SwedenBIO Award as Late-Stage Pipeline Advances
Premium
Company Announcements
Hansa Biopharma Wins 2025 SwedenBIO Award as Late-Stage Pipeline Advances
1M ago
Hansa Biopharma initiated with an Outperform at Wedbush
Premium
The Fly
Hansa Biopharma initiated with an Outperform at Wedbush
2M ago
Hansa Biopharma Files FDA BLA for Imlifidase in High-Risk Kidney Transplant Patients
PremiumCompany Announcements
Hansa Biopharma Files FDA BLA for Imlifidase in High-Risk Kidney Transplant Patients
2M ago
Hansa Biopharma to Present at J.P. Morgan Healthcare Conference to Boost Investor Visibility
PremiumCompany Announcements
Hansa Biopharma to Present at J.P. Morgan Healthcare Conference to Boost Investor Visibility
2M ago
Hansa Biopharma price target lowered to SEK 111 from SEK 132 at H.C. Wainwright
PremiumThe Fly
Hansa Biopharma price target lowered to SEK 111 from SEK 132 at H.C. Wainwright
2M ago
Hansa Biopharma’s Phase 3 Trial for Anti-GBM Disease Shows Mixed Results
PremiumCompany Announcements
Hansa Biopharma’s Phase 3 Trial for Anti-GBM Disease Shows Mixed Results
2M ago
Hansa Biopharma Strengthens European and International Operations
PremiumCompany AnnouncementsHansa Biopharma Strengthens European and International Operations
2M ago
Hansa Biopharma’s Growth Potential: Buy Rating Backed by Promising Idefirix Trials and Expanding Pipeline
Premium
Ratings
Hansa Biopharma’s Growth Potential: Buy Rating Backed by Promising Idefirix Trials and Expanding Pipeline
3M ago
Hansa Biopharma to Present at Major Healthcare Conferences
Premium
Company Announcements
Hansa Biopharma to Present at Major Healthcare Conferences
3M ago
Optimistic Buy Rating for Hansa Biopharma AB: Imlifidase’s Potential in Kidney Transplantation Highlighted by Key Opinion Leaders
PremiumRatings
Optimistic Buy Rating for Hansa Biopharma AB: Imlifidase’s Potential in Kidney Transplantation Highlighted by Key Opinion Leaders
3M ago
Hansa Biopharma Hosts Virtual Event on Imlifidase Phase 3 Results
PremiumCompany Announcements
Hansa Biopharma Hosts Virtual Event on Imlifidase Phase 3 Results
3M ago
Hansa Biopharma Engages in Key Industry Conferences
PremiumCompany Announcements
Hansa Biopharma Engages in Key Industry Conferences
4M ago
Optimistic Outlook for Hansa Biopharma AB Despite European Sales Challenges: Focus on Imlifidase Potential and US Market Entry
PremiumRatings
Optimistic Outlook for Hansa Biopharma AB Despite European Sales Challenges: Focus on Imlifidase Potential and US Market Entry
4M ago
Hansa Biopharma’s Earnings Call: U.S. Prospects Amid European Challenges
PremiumCompany AnnouncementsHansa Biopharma’s Earnings Call: U.S. Prospects Amid European Challenges
4M ago
Hansa Biopharma Expands Share Capital with New Share Issue
Premium
Company Announcements
Hansa Biopharma Expands Share Capital with New Share Issue
4M ago
Hansa Biopharma’s Imlifidase Achieves Key Milestone in U.S. Phase 3 Trial
Premium
Company Announcements
Hansa Biopharma’s Imlifidase Achieves Key Milestone in U.S. Phase 3 Trial
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >